Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MabVax ovarian cancer vaccine
- Development stage
- Discontinued
- Lead developer
- MabVax Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MabVax Therapeutics developed a therapeutic polyvalent vaccine for ovarian cancer, licensed from Memorial Sloan Kettering Cancer Center (MSKCC). The vaccine is designed to stimulate the immune system to recognize and target multiple carbohydrate-based antigens frequently expressed on the surface of ovarian cancer cells, including Globo H, Lewis Y, GM2, Sialyl-Tn (sTn), and Thomsen-Friedenreich (TF) antigen. These antigens are conjugated to a carrier protein, Keyhole Limpet Hemocyanin (KLH), and administered with the saponin-based adjuvant QS-21 to enhance immunogenicity. The vaccine was advanced into a proof-of-concept Phase 2 multi-center clinical trial for patients with recurrent ovarian cancer. MabVax's broader strategy utilized these vaccines to identify and recover fully human monoclonal antibodies from responding patients, leading to the development of other therapeutic assets.
- Other names
- polyvalent carbohydrate vaccineMSKCC ovarian cancer vaccinepolyvalent ovarian cancer vaccine
02
Targets
Globo-HTF antigen (Thomsen-Friedenreich antigen)GM2 (Ganglioside GM2)Tn (Tn antigen)STn-MUC1 (Sialyl-Tn-MUC1)
Beyond the preview
Go deeper on MabVax ovarian cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MabVax ovarian cancer vaccine.